Literature DB >> 1501508

The search for tumor-associated proteins in pleural effusions by means of monoclonal antibodies and a dot blot assay.

M Lawniczak1, J Sikora, P Kania, J Zeromski.   

Abstract

Liquid moiety of 61 pleural effusions was tested for tumor-associated proteins (TAP) by means of a dot immunobinding (dot blot) assay (DIA) and a panel of monoclonal antibodies (Moabs). The sensitivity of the assay was checked using a purified, serially diluted carcinoembryonic antigen (CEA) preparation and an anti-CEA monoclonal IgG system. The latter was examined using both DIA and enzyme-linked immunosorbent assay ELISA solid phase assays in simulated conditions that mimicked the protein content of effusions. Finally, the results of DIA were compared to the immunohistochemistry carried out on cell sediments from the same effusions with similar Moabs. It was found that the prevalence of several TAPs, including CEA, epithelial membrane antigen (EMA), vimentin, tenascin, and Thomsen Friedenreich antigen, was significantly higher in the malignant effusions than in the nonmalignant ones. A total, larger than 2, of detected TAPs in a given fluid, was found almost exclusively in malignant effusions (p less than 0.0001). The detection limit of the DIA for a CEA was determined at 5 ng/ml, while for the ELISA it was 1 ng/ml. Several TAPs, especially the CEA, could be detected in parallel tests, carried out on the liquid moiety and the cell sediments of malignant effusions. The evaluation of selected TAPs in pleural effusions by dot blot assay may be of clinical value.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501508     DOI: 10.1007/bf00175978

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  17 in total

1.  Epitope specificity and cross-reactivity pattern of a large series of monoclonal antibodies to carcinoembryonic antigen.

Authors:  A Hedin; F Zoubir; T Lundgren; S Hammarström
Journal:  Mol Immunol       Date:  1986-10       Impact factor: 4.407

2.  Expression of epithelial and neural antigens in small cell and non small cell lung carcinoma.

Authors:  F Moss; L G Bobrow; M N Sheppard; M Griffiths; D Rowe; P C Beverley; B Addis; R L Souhami
Journal:  J Pathol       Date:  1986-06       Impact factor: 7.996

Review 3.  Tenascin: a hexameric adhesive glycoprotein.

Authors:  P G Natali; L Zardi
Journal:  Int J Cancer Suppl       Date:  1989

4.  Differences in domain structure between human fibronectins isolated from plasma and from culture supernatants of normal and transformed fibroblasts. Studies with domain-specific antibodies.

Authors:  K Sekiguchi; A Siri; L Zardi; S Hakomori
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

5.  A dot-immunobinding assay for monoclonal and other antibodies.

Authors:  R Hawkes; E Niday; J Gordon
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

6.  Human lung tumours may coexpress different classes of intermediate filaments.

Authors:  K C Gatter; M S Dunnill; G N Van Muijen; D Y Mason
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

7.  Tenascin interferes with fibronectin action.

Authors:  R Chiquet-Ehrismann; P Kalla; C A Pearson; K Beck; M Chiquet
Journal:  Cell       Date:  1988-05-06       Impact factor: 41.582

8.  Detection of malignant pleural effusions by tumor marker evaluation.

Authors:  F Pavesi; M Lotzniker; P Cremaschi; L Marbello; L Acquistapace; R Moratti
Journal:  Eur J Cancer Clin Oncol       Date:  1988-06

9.  Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.

Authors:  L Borsi; B Carnemolla; P Castellani; C Rosellini; D Vecchio; G Allemanni; S E Chang; J Taylor-Papadimitriou; H Pande; L Zardi
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

10.  Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor.

Authors:  B Y Rubin; S L Anderson; S A Sullivan; B D Williamson; E A Carswell; L J Old
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.